We are live on ! Find out more
TAM

TFG Asset Management Portfolio holdings

AUM $635M
1-Year Est. Return 28.07%
This Fund
S&P 500
This Quarter Est. Return
+13.2%
1 Year Est. Return
+28.07%
3 Year Est. Return
+72.07%
5 Year Est. Return
+87.41%
10 Year Est. Return
+132.97%
AUM
$635M
AUM Growth
+$120M
Cap. Flow
+$71.2M
Cap. Flow %
11.21%
Top 10 Hldgs %
74.01%
Holding
46
New
10
Increased
16
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
PATH icon
UiPath
PATH
+$61.3M
2
ALKT icon
Alkami Technology
ALKT
+$9.91M
3
CELC icon
Celcuity
CELC
+$7.4M
4
RLAY icon
Relay Therapeutics
RLAY
+$5.64M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$4.17M

Top Sells

Rank Stock Value
1
WBD icon
Warner Bros
WBD
+$18.2M
2
PRAX icon
Praxis Precision Medicines
PRAX
+$5.14M
3
AXSM icon
Axsome Therapeutics
AXSM
+$4.35M
4
SLNO
Soleno Therapeutics
SLNO
+$3.42M
5
MPLT
MapLight Therapeutics
MPLT
+$2.28M

Sector Composition

Rank Sector Weight
1 Technology 61.09%
2 Healthcare 29.27%
3 Energy 5.33%
4 Miscellaneous 3.27%
5 Communication Services 1.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PATH icon
1
UiPath
PATH
$9.4B
$336M 52.98%
30,950,000
+5,742,372
+23% +$61.3M
KGEI
2
Kolibri Global Energy
KGEI
$209M
$33.8M 5.33%
6,834,504
– –
AUTL
3
Autolus Therapeutics
AUTL
$623M
$15.2M 2.39%
9,500,000
– –
LYFT icon
4
Lyft
LYFT
$6.7B
$14.6M 2.3%
1,000,000
– –
DFTX
5
Definium Therapeutics
DFTX
$5.51B
$13.5M 2.13%
286,990
+86,996
+43% +$2.15M
WK icon
6
Workiva
WK
$4.31B
$12.1M 1.91%
250,000
– –
CXM icon
7
Sprinklr
CXM
$1.91B
$11.4M 1.79%
2,200,000
– –
MBX
8
MBX Biosciences
MBX
$3.03B
$11.2M 1.77%
203,543
+58,063
+40% +$2.03M
ALKT icon
9
Alkami Technology
ALKT
$2.16B
$10.9M 1.71%
+600,284
New +$9.91M
CLDX icon
10
Celldex Therapeutics
CLDX
$3.07B
$10.8M 1.7%
290,441
-21,875
-7% -$707K
RLAY icon
11
Relay Therapeutics
RLAY
$4.11B
$10.7M 1.68%
570,311
+388,768
+214% +$5.64M
ARWR icon
12
Arrowhead Research
ARWR
$12B
$10.6M 1.67%
130,484
+3,286
+3% +$243K
PHVS icon
13
Pharvaris
PHVS
$2.48B
$10.2M 1.61%
295,627
+74,016
+33% +$2.24M
ALKS icon
14
Alkermes
ALKS
$7.95B
$9.95M 1.57%
189,979
+30,188
+19% +$1.18M
IMVT icon
15
Immunovant
IMVT
$8.51B
$9.86M 1.55%
255,934
+37,427
+17% +$1.14M
AXSM icon
16
CALL
Axsome Therapeutics
AXSM
$10.4B
$8.57M 1.35%
35,000
– –
SLN
17
Silence Therapeutics
SLN
$834M
$8.39M 1.32%
764,256
+134,095
+21% +$943K
DYN icon
18
Dyne Therapeutics
DYN
$4.68B
$7.92M 1.25%
356,657
+98,525
+38% +$1.83M
IONS icon
19
Ionis Pharmaceuticals
IONS
$10.1B
$7.7M 1.21%
97,173
+55,409
+133% +$4.17M
AGIO icon
20
Agios Pharmaceuticals
AGIO
$1.99B
$7.63M 1.2%
205,579
+40,740
+25% +$1.24M
HRMY icon
21
Harmony Biosciences
HRMY
$2.28B
$7.32M 1.15%
201,036
+81,696
+68% +$2.58M
KRYS icon
22
Krystal Biotech
KRYS
$10.4B
$7.31M 1.15%
19,668
– –
ANNX icon
23
Annexon
ANNX
$942M
$7.09M 1.12%
1,242,455
-50,000
-4% -$276K
CELC icon
24
Celcuity
CELC
$4.33B
$6.71M 1.06%
+64,110
New +$7.4M
WBD icon
25
Warner Bros
WBD
$72.1B
$6.67M 1.05%
250,000
-673,725
-73% -$18.2M
1
2

Similar funds

GRR
Golden Reserve Retirement Dublin, Ohio $635M AUM 25.04% 1-Year Est. Return
GAM
Gould Asset Management Claremont, California $635M AUM 14.36% 1-Year Est. Return
MPIA
Mountain Pacific Investment Advisers Boise, Idaho $635M AUM 26.7% 1-Year Est. Return
AFG
Altiora Financial Group Lebanon, Ohio $634M AUM 13.93% 1-Year Est. Return
MWA
Martel Wealth Advisors Vancouver, Washington $636M AUM 12.74% 1-Year Est. Return
MCM
Maytus Capital Management New York $636M AUM 131.32% 1-Year Est. Return
MAM
Milestone Asset Management Pittsburgh, Pennsylvania $636M AUM 22.1% 1-Year Est. Return
BAM
BOCHK Asset Management Hong Kong $634M AUM 64.99% 1-Year Est. Return

TFG Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, TFG Asset Management held 46 positions worth $635M, up 23% from $515M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

TFG Asset Management deployed $71.2M of net new capital in Q2 2026, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was Alkami Technology: 600,284 shares worth $10.9M.

By sector, the portfolio is most concentrated in Technology at 61% of assets, down from 63% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Warner Bros, an estimated $18.2M trimmed.

  • TFG Asset Management's largest Q2 2026 buy was Alkami Technology: 600,284 shares worth $10.9M.
  • TFG Asset Management added most to UiPath in Q2 2026, an estimated $61.3M increase.
  • TFG Asset Management's biggest Q2 2026 reduction was Warner Bros, cutting an estimated $18.2M.
  • TFG Asset Management fully exited Praxis Precision Medicines in Q2 2026, selling an estimated $5.14M.
  • TFG Asset Management's ten largest holdings make up 74% of its $635M portfolio in Q2 2026.
  • TFG Asset Management opened 10 new positions and closed 7 in Q2 2026.
  • TFG Asset Management's portfolio value rose 23% quarter-over-quarter to $635M.

Based on TFG Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.